[Newsmp] Dupixent, a biologic medication that was approved for insurance benefits only for adults with atopic dermatitis, was also recognized for its reasonableness in children and adolescents.
The Health Insurance Review and Assessment Service (HIRA) held the first Drug Benefit Evaluation Committee in 2023 on the 12th.
HIRA reviewed the adequacy of reimbursement for Sanofi-Aventis Korea’s Dupixent Prefilled Inj. 200mg and 300mg (ingredient: dupilumab) and evaluated that the benefit was reasonable for atopic dermatitis in children and adolescents.
저작권자 © 의약뉴스 무단전재 및 재배포 금지
